ArticleBiomedical reports2025
Effects of aged garlic extract may differ between normal cells and cancer cells.
Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Healing Effect of Aged Garlic Extract on Acetic Acid and 5-Fluorouracil-Induced Oral Mucositis in Mice.Journal of clinical medicine research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aged garlic extract (AGE) is one of the widely used garlic-based products that are extensively studied and are commercially available. However, there are no reports that compare the effects of AGE on normal cells and oral cancer cells. The present study tried to investigate the effects of AGE on normal healthy cells and cancer cells. The effect of AGE on the proliferation of normal cell lines HaCaT and fibroblast, in addition to cancer cell lines SCC7, HSC2, HSC3 and Ca9-22 were evaluated by MTT assay. The effects of AGE on cell migration were examined using wound healing and migration assays. Whole transcriptome analysis, ingenuity pathways analysis (IPA) and western blot analysis were used to investigate the mechanism of action of AGE in HaCaT and SCC7 cells. Data from the aforementioned assays were then evaluated and compared to assess if AGE affects normal cells differently compared with cancer cells. AGE was found to promote the proliferation and migration of normal cells, especially HaCaT, in the absence of FBS more markedly compared with those of cancer cells. However, AGE could not promote wound healing in fibroblast cells at the same rate as in HaCaT cells. In normal cells, sequential or combination AGE treatment with 5-fluorouracil (5-FU), cisplatin (CDDP) and docetaxel (DOC) somewhat counteracted the proliferation-limiting effects of anti-cancer agents. However, in cancer cells, AGE treatments enhanced the inhibitory effects of anti-cancer agents when used in combination with 5-FU, CDDP or DOC. This observation was more evident in the case of pre-treatment with anticancer agents followed by AGE sequential treatment. Subsequently, whole transcriptome analysis and IPA data suggested that AGE facilitated the proliferation and survival of normal cells through the induction of protein kinase B family protein and brain-derived neurotrophic factor pathways, whilst suppressing ferroptosis These data were also confirmed by western blotting to see if the genetic changes shown in whole transcriptome analysis and IPA are also induced at the protein level. In addition, AGE may reduce cancer cell proliferation through the suppression of cancer metastasis signaling and enhancement of phagocytic activity according to whole transcriptome analysis and IPA data. Taken together, these findings suggested that AGE may prompt the proliferation of normal cells and suppress the that of cancer cells through different cellular processes and signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.